NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS » TOP China Pharmas » Simcere Pharmaceutical Group back to previous page show list
Simcere Pharmaceutical Group »04/09/2008 [Company watch]
Simcere Shows Positive Data from Cancer Drug Trial

Simcere Pharma (SCR) reported that interim results from a Phase IV trial of its patented anti-cancer drug Endu showed the drug displayed both safety and efficacy. The data were in line with Endu’s Phase III trial. An anti-angiogenesis drug, Endu is a modified version of recombinant human endostatin. It is approved for use in China against non-small cell lung cancer, administered as an adjunct to platinum-class chemotherapy. Simcere said the results showed that Endu has a synergistic effect in this patient population, though the trial did not include patients who received platinum-class chemotherapy by itself. After 648 patients, Endu produced overall response rates of 24% and therapeutic activity in 81% of patients. In newly-treated patients, the response rate was 31%, a level that dropped to 17% in previously treated patients. Similar to the response rate, the drug was tolerated by patients at about the same levels as was evident in the Phase III trial. The trial has a single arm, open label design. In the trial, Endu has been administered to more than 2000 patients with advanced-stage NSCLC. Full results from the Phase IV test are expected in 2010. When the company announced its Q2 results, Simcere said the fall-off in Endu revenue during the period was due to the Phase IV trial. Patients meeting the trial’s criteria receive the drug for free. Endu is approved as a first-line treatment for NSCLC in China.

 

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.